Similar articles

• Commentary: comparators in H. pylori eradication--stating the ethics of statins.

  McNicholl AG, Gisbert JP. McNicholl AG, et al. Aliment Pharmacol Ther. 2012 Aug;36(4):400-1. doi: 10.1111/j.1365-2036.2012.05191.x. Aliment Pharmacol Ther. 2012. PMID: 22803647 No abstract available.
• Commentary: simvastatin as the key to improving H. pylori eradication rates?

  den Hollander WJ, Kuipers EJ. den Hollander WJ, et al. Aliment Pharmacol Ther. 2012 Sep;36(5):493; author reply 494. doi: 10.1111/j.1365-2036.2012.05195.x. Aliment Pharmacol Ther. 2012. PMID: 22860610 No abstract available.
• Commentary: something new to consider in the treatment of Helicobacter pylori infection? Authors' reply.

  Nseir W, Mograbi J, Abu-Elheja O. Nseir W, et al. Aliment Pharmacol Ther. 2012 Aug;36(4):399-400. doi: 10.1111/j.1365-2036.2012.05192.x. Aliment Pharmacol Ther. 2012. PMID: 22803646 No abstract available.
• [Helicobacter pylori: what schemes of eradication are essential today?].

  Maev IV, Samsonov AA, Golubev NN. Maev IV, et al. Ter Arkh. 2011;83(8):41-4. Ter Arkh. 2011. PMID: 21961331 Review. Russian.
• [The present status and problems of Helicobacter pylori first-line eradication therapy].

  Tokunaga K, Tanaka A, Sugano H, Takahashi S. Tokunaga K, et al. Nihon Rinsho. 2009 Dec;67(12):2291-6. Nihon Rinsho. 2009. PMID: 19999114 Review. Japanese.